#130: Ganesh Swami on Granular Historical Data, Covalent and NFTs

Ganesh Swami is a serial entrepreneur, adventurer, and speaker. He is currently the co-founder and CEO of Covalent – a venture-funded blockchain data analytics startup based out of Vancouver, BC. He has over a decade of experience with database technology and bringing new products to market. His current focus with Covalent is to solve the big problems inhibiting blockchain's mainstream adoption. He started his career in building protein simulation algorithms to solve cancer.In this conversation, we discuss:- Building protein simulation algorithms to solve cancer- How P2E games are becoming such a hot topic and what we found in our analysis- Why people need granular, historical data, and how accessible they are- How developers and analysts can use our Unified API for free, without coding- How Covalent help with TAX seasons- What is on-chain analysis, why do people need them- Granular, historical data, and how accessible they are- $25mil in funding to data verification space CovalentWebsite: covalenthq.com Twitter: @Covalent_HQDiscord: covalenthq.com/discordGanesh Swami Twitter: @gane5h LinkedIn: Ganesh Swami---------------------------------------------------------------------------------  This episode is brought to you by PrimeXBT.  PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.  PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions.  Code: CRYPTONEWS50  This promotion is available for a month after activation. Click the link below:  PrimeXBT x CRYPTONEWS50

There are no comments yet.

Please log in to write the first comment.